187 related articles for article (PubMed ID: 27051973)
1. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.
Scheinberg MA; Hislop CM; Martin RS
Expert Opin Biol Ther; 2016; 16(5):723-33. PubMed ID: 27051973
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
Lenert A; Niewold TB; Lenert P
Drug Des Devel Ther; 2017; 11():747-757. PubMed ID: 28331294
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
4. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
Stohl W; Merrill JT; Looney RJ; Buyon J; Wallace DJ; Weisman MH; Ginzler EM; Cooke B; Holloway D; Kaliyaperumal A; Kuchimanchi KR; Cheah TC; Rasmussen E; Ferbas J; Belouski SS; Tsuji W; Zack DJ
Arthritis Res Ther; 2015 Aug; 17(1):215. PubMed ID: 26290435
[TBL] [Abstract][Full Text] [Related]
5. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
Petri MA; Martin RS; Scheinberg MA; Furie RA
Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
Stohl W
Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
[TBL] [Abstract][Full Text] [Related]
7. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
Stohl W
Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
10. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Samy E; Wax S; Huard B; Hess H; Schneider P
Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
12. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
13. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
Stohl W
Curr Rheumatol Rep; 2012 Aug; 14(4):303-9. PubMed ID: 22547203
[TBL] [Abstract][Full Text] [Related]
14. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
15. Update on belimumab for the management of systemic lupus erythematosus.
Lutalo PM; D'Cruz DP
Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
[TBL] [Abstract][Full Text] [Related]
16. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.
Fairfax K; Mackay IR; Mackay F
IUBMB Life; 2012 Jul; 64(7):595-602. PubMed ID: 22641424
[TBL] [Abstract][Full Text] [Related]
17. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
18. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
19. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
Sanchez-Niño MD; Ortiz A
Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
[TBL] [Abstract][Full Text] [Related]
20. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
Vincent FB; Morand EF; Mackay F
Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
